Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc > 9 billion

<< Previous

Bullboard Posts

Next >>

Comment by Francine01on Jan 13, 2021 3:00pm

244 Views

Post# 32286819

RE:9 billion

No clue who could be the buyer or shareholder of control of Acasti.

But Yes, it could come from the Asian market.

Remember in November 2017, Acasti signed a agreement with a Chinese pharma.

Asian market is not bounded by FDA requirements.

They could pretend 43% reduction for HTG.

Aker was Neptune OM3 buyer, this could make sense if they want to commercialize Capre and do a small ph3 vs Amarin or relunch ph 3.

<< Previous

Bullboard Posts

Next >>

Sony shuts down Firewalk Studios after ‘Concord’ crash